2014
DOI: 10.1517/13543776.2014.947268
|View full text |Cite
|
Sign up to set email alerts
|

PTP1B inhibitors for type 2 diabetes treatment: a patent review (2011 – 2014)

Abstract: PTP1B inhibitors show beneficial effects to enhance sensibility of IR by restricting the activity of enzyme and have favorable curing effects. However, structural homologies in the catalytic domain of PTP1B with other protein tyrosine phosphatases (PTPs) like leukocyte common antigen-related, CD45, SHP-2 and T-cell-PTP present a challenging task of achieving selectivity. Thus, for therapeutic application of PTP1B inhibitors, highly selective molecules exhibiting desired effects without side effects are expecte… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
58
0

Year Published

2015
2015
2024
2024

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 111 publications
(58 citation statements)
references
References 98 publications
0
58
0
Order By: Relevance
“…Considering that PTP1B directly dephosphorylates insulin receptors and the receptor substrate, thereby negatively regulating the insulin signaling pathway, it may also have a direct effect on its downstream pathways by affecting the activity or expression of insulin signal transduction molecules to inhibit insulin signal transduction, leading to insulin resistance [36,37]. We expected CPOP to be useful in the treatment of type II diabetes [38].…”
Section: Resultsmentioning
confidence: 99%
“…Considering that PTP1B directly dephosphorylates insulin receptors and the receptor substrate, thereby negatively regulating the insulin signaling pathway, it may also have a direct effect on its downstream pathways by affecting the activity or expression of insulin signal transduction molecules to inhibit insulin signal transduction, leading to insulin resistance [36,37]. We expected CPOP to be useful in the treatment of type II diabetes [38].…”
Section: Resultsmentioning
confidence: 99%
“…5 For this reason, PTP1B has received attention over the last few years as a novel therapeutic target for the treatment of diabetes and obesity, and as such there are numerous inhibitors against PTP1B at various stages of development. 6 …”
mentioning
confidence: 99%
“…effects (Tamrakar et al, 2014). The representative compound is MSI-1436 (Trodusquemine) which can suppress appetite and causes fat-specific weight loss in diet-induced obese mice and it is in phase I trial (Scott et al, 2010).…”
Section: Discussionmentioning
confidence: 99%